Explore

Rapid Read Rapid Read
SORLA Protein Shows Promise in Protecting Against Tau Tangles in Alzheimer's Research

SORLA Protein Shows Promise in Protecting Against Tau Tangles in Alzheimer's Research

Researchers at Sanford Burnham Prebys have discovered that the protein SORLA may offer protection against the harmful effects of tau tangles, which are associated with Alzheimer's disease and other neurodegenerative conditions. In a study published in Science Advances, the team led by Timothy Huang, PhD, demonstrated that overexpression of SORLA in a mouse model reduced tau hyperphosphorylation, synaptic loss, and glial hyperactivation. These findings suggest that SORLA could be a potential therapeutic target for treating tauopathies, which are characterized by the accumulation of tau proteins that disrupt neuronal circuits. The study involved crossbreeding mice to produce extra human SORLA protein, which showed a protective effect against tau-related damage.
Rapid Read Rapid Read
University of Kentucky Researchers Identify New Alzheimer's Sleep Loss Mechanism

University of Kentucky Researchers Identify New Alzheimer's Sleep Loss Mechanism

Researchers at the University of Kentucky have discovered a new mechanism behind sleep loss in Alzheimer's disease, focusing on the role of microglia, the brain's immune cells. The study, published in Alzheimer's & Dementia, reveals that these cells are the primary drivers of sleep disruption in an animal model of Alzheimer's. By using a drug to temporarily eliminate most microglia, the researchers were able to restore over two hours of sleep per day in the affected animals. This finding challenges the previous belief that sleep loss was mainly due to damaged neurons or amyloid plaques. The study utilized advanced tools like EEG and EMG to monitor brain activity and sleep patterns, providing a comprehensive view of the brain's immune response.
Rapid Read Rapid Read
University of Kentucky Researchers Discover New Alzheimer's Sleep Loss Mechanism

University of Kentucky Researchers Discover New Alzheimer's Sleep Loss Mechanism

Researchers at the University of Kentucky have identified a new mechanism contributing to sleep loss in Alzheimer's disease. The study, led by Shannon L. Macauley, Ph.D., and Nicholas J. Constantino, Ph.D., found that microglia, the brain's immune cells, are the primary drivers of sleep disruption in an animal model of Alzheimer's. By using a drug to temporarily eliminate most of these cells, the researchers were able to restore over two hours of sleep per day in the affected animals. This discovery challenges the previous understanding that sleep loss was mainly due to damaged neurons or amyloid plaques, suggesting instead that a broader immune response is responsible.
Rapid Read Rapid Read
Alzheimer's Research Identifies Microglia as Key to Sleep Restoration Without Plaque Removal

Alzheimer's Research Identifies Microglia as Key to Sleep Restoration Without Plaque Removal

Researchers at the University of Kentucky have discovered that microglia, the brain's immune cells, are major contributors to sleep loss in Alzheimer's disease. By using the cancer drug Pexidartinib to temporarily remove these cells in mice, the study found significant improvements in sleep without reducing amyloid plaque levels. This suggests that the inflammatory response to plaques, rather than the plaques themselves, may be a reversible cause of sleep disruption, offering a new potential treatment target for Alzheimer's.
Trendline Trendline
Challenges in Drug Discovery Highlight Need for Human-Centric Preclinical Models

Challenges in Drug Discovery Highlight Need for Human-Centric Preclinical Models

Challenges in Drug Discovery Highlight Need for Human-Centric Preclinical Models
Trendline Trendline
Cellares and Papillon Therapeutics Collaborate to Automate Gene Therapy Manufacturing for Friedreich's Ataxia

Cellares and Papillon Therapeutics Collaborate to Automate Gene Therapy Manufacturing for Friedreich's Ataxia

Cellares and Papillon Therapeutics Collaborate to Automate Gene Therapy Manufacturing for Friedreich's Ataxia
Trendline Trendline
Innate Pharma Completes Enrollment in Phase 1 Study of IPH4502, Targeting Advanced Solid Tumors

Innate Pharma Completes Enrollment in Phase 1 Study of IPH4502, Targeting Advanced Solid Tumors

Innate Pharma Completes Enrollment in Phase 1 Study of IPH4502, Targeting Advanced Solid Tumors
Trendline Trendline
Colossal Biosciences Seeks New Funding Amidst Valuation Surge to $30 Billion

Colossal Biosciences Seeks New Funding Amidst Valuation Surge to $30 Billion

Colossal Biosciences Seeks New Funding Amidst Valuation Surge to $30 Billion
Rapid Read Rapid Read
Umeå University Develops Antibody Drug to Halt Aggressive Prostate Cancer Spread

Umeå University Develops Antibody Drug to Halt Aggressive Prostate Cancer Spread

Researchers at Umeå University, in collaboration with other institutions, have developed an experimental antibody drug aimed at slowing tumor growth and preventing the spread of aggressive prostate cancer. The study, published in Signal Transduction and Targeted Therapy, highlights the creation of a fully human antibody designed to prevent metastasis. This antibody, made entirely from human proteins, has shown promise in preclinical studies by stopping tumor growth and metastatic spread in aggressive prostate cancer. The research, led by Professor Maréne Landström, identifies a new mechanism that could potentially lower the risk of side effects. The development of this drug is a significant step towards creating a treatment that could improve survival rates and quality of life for men with advanced prostate cancer.
Trendline Trendline
CRISPR Technology Advances with Epigenetic Editing in Clinical Trials

CRISPR Technology Advances with Epigenetic Editing in Clinical Trials

CRISPR Technology Advances with Epigenetic Editing in Clinical Trials
Rapid Read Rapid Read
Inflammasome Therapeutics Announces Promising Phase 2 Results for K8 in Geographic Atrophy

Inflammasome Therapeutics Announces Promising Phase 2 Results for K8 in Geographic Atrophy

Inflammasome Therapeutics has reported positive results from a Phase 2 clinical trial of its investigational drug K8 for the treatment of geographic atrophy (GA), a severe form of dry age-related macular degeneration. The trial demonstrated that K8 significantly slowed the progression of GA and improved visual acuity over a six-month period. The study involved 30 participants with bilateral GA, and the drug was administered as a bioerodible sustained-release intravitreal implant. The 0.7 mg dose cohort showed a 54% reduction in the mean rate of GA growth compared to the control group, and a 4.0-letter mean advantage in best-corrected visual acuity was observed. These results were presented at the American Society of Retina Specialists Annual Meeting in Montreal.
Trendline Trendline
Incyte Presents Promising Data on Cancer Treatments at ESMO Congress 2026

Incyte Presents Promising Data on Cancer Treatments at ESMO Congress 2026

Incyte Presents Promising Data on Cancer Treatments at ESMO Congress 2026